4.1 Article

Wortmannin, a widely used phosphoinositide 3-kinase inhibitor, also potently inhibits mammalian polo-like kinase

Journal

CHEMISTRY & BIOLOGY
Volume 12, Issue 1, Pages 99-107

Publisher

CELL PRESS
DOI: 10.1016/j.chembiol.2004.11.009

Keywords

-

Funding

  1. NCI NIH HHS [2R44 CA 097462-02] Funding Source: Medline
  2. NATIONAL CANCER INSTITUTE [R44CA097462] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Polo-like kinases (PLKs) play critical roles throughout mitosis. Here, we report that wortmannin, which was previously thought to be a highly selective inhibitor of phosphoinositide (PI) 3-kinases, is a potent inhibitor of mammalian PLK1. Observation of the wortmannin-PLK1 interaction was enabled by a tetra-methylrhodamine-wortmannin conjugate (AX7503) that permits rapid detection of PLK1 activity and expression in complex proteomes. Importantly, we show that wortmannin inhibits PLK1 activity in an in vitro kinase assay with an IC50 of 24 nM and when incubated with intact cells. Taken together, our results indicate that, at the concentrations of wortmannin commonly used to inhibit PI 3-kinases, PLK1 is also significantly inhibited.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available